Oncology has entered a period of profound technological change. As treatments grow increasingly complex, oncologists must make rapid, high-stakes decisions while also managing demanding administrative tasks, safety checks, and long-term documentation. Digital platforms have become indispensable in navigating these pressures, offering a way to streamline workflows, reduce manual errors, and support evidence-based care. Within this global shift toward digitally enabled cancer treatment, Altai Oncology stands out as a company that has built a comprehensive, oncology-specific ecosystem designed for the realities of modern cancer care.
Altai Inc., operating under the Altai Oncology brand, was founded in 2013 by Ulas Darda Bayraktar. The company’s headquarters are in Sheridan, Wyoming, while its research and development operations are based in Ankara, Turkey. This dual structure allows Altai to maintain both regulatory compliance and high-velocity development cycles. The company holds ISO 13485 certification, reflecting its commitment to medical-device quality management standards, and its flagship system, the Altai Oncology Suite, is marked with CE marking as a Class IIb medical device. These credentials position Altai as a trusted provider of oncology informatics for hospitals, cancer institutes, and infusion centers.
The Altai Oncology Suite functions as a unified digital environment that manages the entire chemotherapy lifecycle—from initial treatment planning to pharmacy preparation and infusion administration. The software integrates chemotherapy order entry, dose calculation, protocol selection, documentation, scheduling, drug inventory management, and cancer registry functions into a single cohesive system. Clinicians can choose standardized protocols, adjust regimens based on patient-specific parameters, and generate complete treatment plans without needing disconnected tools or manual calculations. Dose computations are performed automatically using validated formulas and current laboratory values, which help to improve precision and reduce the likelihood of calculation errors. Safety features such as drug-interaction warnings, allergy checks, dual-dose verification, and cumulative-dose limits offer additional safeguards throughout the process.
A defining strength of the system is its extensive protocol library, which has been continually curated since 2015 and now includes more than 1,000 oncology and hematology treatment protocols. These protocols cover chemotherapy, immunotherapy, targeted therapies, supportive-care pathways, and transplantation regimens. Each entry provides detailed clinical guidance, including dosing, administration steps, monitoring requirements, and laboratory criteria. The library is regularly updated to incorporate new research findings, regulatory approvals, and guideline revisions, aiming that oncologists have access to current standards of care. Institutions may also create their own custom protocols within the system, allowing them to integrate institutional pathways, clinical-trial regimens, or locally adapted treatment strategies.
In recognition of the increasing role of mobile technology in healthcare, Altai has extended its ecosystem to include the Altai Oncology Mobile App for iOS and Android. The app gives clinicians access to the full protocol library, dosing calculators, staging modules, and summary references directly from their phones or tablets. This mobile capability supports clinicians during rounds, consultations, and off-site decision-making, offering a seamless complement to the main desktop system. The synchronization between mobile and desktop environments helps treatment information remain consistent across platforms and aligns with data protection requirements.
Altai Oncology also developed its OncoRegistry module to support structured documentation of toxicities, staging details, treatment responses, and long-term outcomes. This registry function helps institutions monitor results over time, conduct internal quality reviews, and generate reliable datasets for research or clinical trials. By standardizing how treatment data is captured, the system enhances continuity of care and supports the shift toward data-driven oncology.
A notable advantage of the Altai Oncology Suite is its high degree of customizability. Oncology practices vary widely in their workflows, resources, staffing, and regulatory environments, and the software can be configured to match these differences with minimal disruption. Scheduling views can be adapted to reflect infusion-chair availability, acuity levels, and staffing assignments. Documentation templates, pharmacy workflows, and clinical pathways can be modified to align with institutional practices. This flexibility allows cancer centers—whether small private clinics or large hospital-based programs—to integrate the software into their existing operations.
Successful implementation of complex clinical software depends not only on features but also on user support and training. Altai Oncology provides structured onboarding for its systems, including Chemo Planner, the Oncology Suite, and OncoRegistry. Training can be delivered remotely or on-site and focuses on protocol management, dose-calculation tools, documentation workflows, and customization options. Ongoing support includes routine updates to the protocol library, system maintenance, user-specific troubleshooting, and assistance from Altai’s U.S. and Turkish operations, helping the company support clients across multiple time zones.
As oncology care becomes increasingly dependent on data accuracy, safety mechanisms, and standardized protocols, solutions like Altai Oncology’s are becoming essential components of clinical infrastructure. The company’s combination of protocol standardization, integrated decision-support tools, customizable workflows, registry functionality, and mobile accessibility reflects a broader trend toward specialized digital ecosystems in cancer care. With its continued investment in research, software development, and clinical collaboration, Altai Oncology is well-positioned to help shape how oncology practices deliver, organize, and study treatment in the years ahead.
